Combined trimethoprim and caspofungin treatment for severe pneumocystis jiroveci pneumonia in a five year old boy with acute lymphoblastic leukemia
Combined trimethoprim and caspofungin treatment for severe pneumocystis jiroveci pneumonia in a five year old boy with acute lymphoblastic leukemia
复制标题
DOI：
10.1055/s-2006-933433
复制
发表时间：
2006-05-01
影响因子：
1
通讯作者：
Goebel, U.
中科院分区：
文献类型：
--
作者：
Beltz, K.;Kramm, C. M.;Goebel, U.
卡泊芬净首次与甲氧苄啶/磺胺甲恶唑（TMP/SMX）一起用于治疗免疫功能低下的儿童高危耶氏肺孢子虫肺炎（PCP）。尽管需要机械通气，但这位复发性急性淋巴细胞白血病的儿科患者在治疗后9天内病情有所改善，没有出现重大副作用。卡泊芬净明显相对缺乏毒性和药代动力学药物相互作用，使其成为一种有吸引力的药物。
Caspofungin was used for the first time with trimethoprim/sulfamethoxazole (TMP/SMX) for treatment of high risk Pneumocystis jiroveci pneumonia (PCP) in a pediatric immunocompromised patient. Despite the need for mechanical ventilation, the pediatric patient with relapsed acute lymphoblastic leukemia improved within nine days of treatment and showed no major side effects. The apparent relative lack of toxicity and of pharmacokinetic drug interactions makes caspofungin an attractive agent.